Skip Navigation


JAC Advance Access originally published online on August 13, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/3/319    most recent
dkg392v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paulsen, D.
Right arrow Articles by Ross, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paulsen, D.
Right arrow Articles by Ross, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 319-323
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects

Denise Paulsen1, Robert Elston2, Wendy Snowden2,*, Margaret Tisdale2 and Lisa Ross1,§

Department of International Clinical Virology, 1 GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA; 2 GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY, UK

Keywords: amprenavir, lopinavir, genotype, resistance, HIV

The first 150 words of the full text of this article appear below.


   Introduction
 
One of the major challenges to the successful long-term treatment of HIV-1 infection is overcoming the development of increasing levels of antiretroviral resistance that often accompany the failure of successive treatment regimens. In order to meet this challenge a good understanding of genotypic resistance profiles and the potential for cross-resistance within each class of antiretrovirals is essential. For the protease inhibitors (PIs), cross-resistance is complex, as a result of the large number of mutations involved. Amprenavir and lopinavir are potent PIs used in ritonavir-boosted regimens, often in patients who have already experienced treatment with other PIs. The resistance profiles of these two PIs overlap to a certain extent but also contain some important differences that can be exploited in the choice of optimal treatment for PI-experienced patients. This article reviews our own research and that of others, in order to clarify the similarities and the differences between the genotypic resistance . . . [Full Text of this Article]


   In vitro and in vivo resistance profiles for amprenavir and lopinavir
 

   The impact of specific mutations on cross-resistance and response to amprenavir and lopinavir in PI-experienced subjects
 

   Cross-resistance between amprenavir and lopinavir
 

   Conclusions
 

   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?